All change on diabetes drug delivery in the EU
This article was originally published in Clinica
The next few years are likely to see the rise of the reusable pen as the drug delivery method for insulin drugs in the $439 million (in 2000) EU diabetes drug delivery market. A new report from Frost & Sullivan* predicts that Italy, France, Spain and the UK will embrace this sophisticated technology to the detriment of syringes, use of which will decline in the coming six years, and insulin pumps.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.